Brickell Biotech, Inc. (BBI)
| Market Cap | 64.75M |
| Revenue (ttm) | 2.46M |
| Net Income (ttm) | -24.41M |
| Shares Out | 28.11M |
| EPS (ttm) | -3.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $1.41 |
| Previous Close | $1.21 |
| Change ($) | 0.20 |
| Change (%) | 16.53% |
| Day's Open | 1.21 |
| Day's Range | 1.20 - 1.45 |
| Day's Volume | 5,542,019 |
| 52-Week Range | 0.48 - 3.15 |
T opline results from the U.S. pivotal Phase 3 program anticipated in the fourth quarter of 2021 Sofpironium bromide gel, 5% (ECCLOCK ® ) recently launched in Japan by development partner, Kak...
Kaken plans to launch ECCLOCK ® for the treatment of primary axillary hyperhidrosis in Japan on November 26, 2020 - - - ECCLOCK ® placed on Japan's National Health Insurance (NHI) drug reimbur...
BOULDER, Colo., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q3 2020 Results - Earnings Call Transcript
Recently completed capital raise expected to fully fund U.S. pivotal Phase 3 program, with topline results anticipated in Q4 2021 - - - Initiated the Cardigan I study, the first of two U.S. pi...
BOULDER, Colo., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
BOULDER, Colo., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
Primary axillary h yperhidrosis is estimated to affect over 1 0 million p eople in the U.S .
Japan is the first country to approve sofpironium bromide with commercial launch expected later this year
BOULDER, Colo., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentia...
Advancement of the U.S. based program will be dependent upon results generated from AnGes’ ongoing and planned clinical studies in Japan Advancement of the U.S. based program will be dependent...
Claims directed to novel crystalline forms of sofpironium bromide
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2020 Results - Earnings Call Transcript
Positive data from the Sofpironium Bromide Phase 3 pivotal study in Japan presented in Q2 2020 by development partner, Kaken Kaken to receive regulatory decision in Japan for sofpironium br...
BOULDER, Colo., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiat...
BOULDER, Colo., June 17, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiat...
Data based on registration study in Japan of sofpironium bromide gel, 5% in patients with primary axillary hyperhidrosis
As tensions continue to rise both domestically and internationally, taking a short position isn't a bad idea. Our deep learning algorithms have identified these 5 companies as the top stocks t...
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q1 2020 Results - Earnings Call Transcript
Announces top-line results from 12-month, Phase 3, long-term safety study Announces top-line results from 12-month, Phase 3, long-term safety study
SFC (formerly known as Startup Funding Club – a UK a seed stage investor – has received £10 million from British Business Investments (the commercial subsidiary of the British Business Bank), ...
Brickell Biotech, Inc. (BBI) CEO Rob Brown on Q4 2019 Results - Earnings Call Transcript
Shares of Brickell Biotech Inc. BBI, +60.86% were vaulted 61% higher on very heavy volume, putting them on track for the biggest one-day gain since the biopharmaceutical company went public 27...
Shares of thinly traded nano-cap biotech Brickell Biotech Inc (NASDAQ: BBI) are skyrocketing on above-average volume Thursday.
BOULDER, Colo., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiat...
BOULDER, Colo., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. and its subsidiary (collectively, “Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on devel...
BOULDER, Colo., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiat...
About BBI
Brickell Biotech, a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. Its pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell Biotech, Inc. has a collaboration agreement with AnGes... [Read more...]
| Industry Biotechnology | Founded 2009 |
| CEO Robert Brown | Employees 15 |
| Stock Exchange NASDAQ | Ticker Symbol BBI |
Financial Performance
In 2019, BBI's revenue was $7.92 million, a decrease of -27.29% compared to the previous year's $10.89 million. Losses were -$23.88 million, 158.5% more than in 2018.